Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction
Massachusetts General Hospital
515 participants
Oct 2, 2020
INTERVENTIONAL
Conditions
Summary
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
Eligibility
Inclusion Criteria2
- Patients with a confirmed diagnosis of HFpEF.
- Age ≥65 years old
Exclusion Criteria6
- End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min)
- no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc
- Negative 99mTc-pyrophosphate scan within a year
- Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan
- Known diagnosis of amyloidosis
- Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)
Interventions
Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05577819